A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab.
Breast Neoplasms|Breast Tumors|Breast Cancer|Locally Recurrent and Metastatic Breast Cancer
DRUG: AMG 706 placebo|DRUG: Bevacizumab|DRUG: AMG 706|DRUG: Paclitaxel
Objective response rate, measured radiologically and assessed by an independent review committee., Last patient enrolled + 16 weeks of treatment
Progression free survival, duration of response, clinical benefit rate (percentage of subjects with complete response, partial response or stable disease lasting >24 weeks), overall survival and incidence of adverse events., >24 weeks
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab.